To elucidate the therapeutic predictive potential of HER3, one intriguing thought is to clarify HER3 expression retrospectively in breast cancer patients who were subsequently treated with adjuvant pertuzumab or novel HER3-targeting antibodies. The gene discussed is ERBB3; the disease is breast cancer.